<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523703</url>
  </required_header>
  <id_info>
    <org_study_id>06-063</org_study_id>
    <nct_id>NCT02523703</nct_id>
  </id_info>
  <brief_title>Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study</brief_title>
  <acronym>EXCEED</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning&#xD;
      most often in subjects aged 20-40 years. In France, thanks to recent studies reported during&#xD;
      general states of MS in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3&#xD;
      / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. In Lower Normandy,&#xD;
      the incidence of MS is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year.&#xD;
&#xD;
      The primary objective of this pilot study is to assess the levels of glutamate and aspartate&#xD;
      (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in&#xD;
      40 patients experiencing an event demyelinating central nervous system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2007</start_date>
  <completion_date type="Actual">February 23, 2015</completion_date>
  <primary_completion_date type="Actual">February 15, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glutamate concentration (in nM)</measure>
    <time_frame>baseline</time_frame>
    <description>comparison between MS patients and controls</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Multiple Sclerosis patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>glutamate and aspartate</intervention_name>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Multiple Sclerosis patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman between 18 and 60 years old.&#xD;
&#xD;
          -  Patient with one or more type of inflammatory events of Central system suggestive of&#xD;
             demyelinating disease (multiple sclerosis, neuromyelitis optical Devic extensive&#xD;
             myelitis)&#xD;
&#xD;
          -  No treatment with corticosteroids for less than 1 month&#xD;
&#xD;
          -  Need for a lumbar puncture performed in the etiologic&#xD;
&#xD;
          -  Need a brain MRI performed within the etiologic&#xD;
&#xD;
          -  Patient who signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary progressive MS&#xD;
&#xD;
          -  Any cons-indication for lumbar puncture&#xD;
&#xD;
          -  Any contra-indication to MRI&#xD;
&#xD;
          -  Minor patient or patient major under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

